• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用DCF化疗和放疗成功治疗原发性前列腺鳞状细胞癌。

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate.

作者信息

Atagi Kaya, Fukuhara Hideo, Ishiguro Motoyoshi, Osakabe Hiroto, Satoshi Fukata, Tamura Kenji, Karashima Takashi, Inoue Keiji

机构信息

Department of Urology Kochi Medical School Kochi Japan.

出版信息

IJU Case Rep. 2021 Aug 23;4(6):421-424. doi: 10.1002/iju5.12365. eCollection 2021 Nov.

DOI:10.1002/iju5.12365
PMID:34755073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8560450/
Abstract

INTRODUCTION

Primary squamous cell carcinoma of the prostate is an extremely rare tumor with poor prognosis. Squamous cell carcinoma of the prostate is estimated to comprise less than 1% of all prostate carcinomas. We report herein a case with clinical response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy with radiotherapy, in a patient with metastatic squamous cell carcinoma of the prostate.

CASE PRESENTATION

A 74-year-old man consulted with frequent urination. The prostate-specific antigen level was 1.62 ng/mL. Multiparametric magnetic resonance imaging showed prostate imaging and reporting and data system category 5 for the whole prostate and biopsy was performed. The pathological diagnosis was pure squamous cell carcinoma of the prostate. fluorodeoxyglucose positron emission tomography showed fluorodeoxyglucose accumulation in the whole prostate and multiple pelvic lymph nodes. Four cycles of docetaxel, cisplatin, and 5-fluorouracil regimen were administrated along with radiotherapy. The patient showed a marked response with no major adverse events.

CONCLUSION

The present case suggests the potential of docetaxel, cisplatin, and 5-fluorouracil chemotherapy with radiotherapy for squamous cell carcinoma of the prostate.

摘要

引言

前列腺原发性鳞状细胞癌是一种极其罕见的肿瘤,预后较差。据估计,前列腺鳞状细胞癌在所有前列腺癌中所占比例不到1%。我们在此报告一例转移性前列腺鳞状细胞癌患者,其对多西他赛、顺铂和5-氟尿嘧啶化疗联合放疗有临床反应。

病例介绍

一名74岁男性因尿频前来就诊。前列腺特异性抗原水平为1.62 ng/mL。多参数磁共振成像显示整个前列腺的前列腺影像报告和数据系统分类为5类,并进行了活检。病理诊断为前列腺纯鳞状细胞癌。氟脱氧葡萄糖正电子发射断层扫描显示整个前列腺和多个盆腔淋巴结有氟脱氧葡萄糖积聚。多西他赛、顺铂和5-氟尿嘧啶方案进行了4个周期的治疗,并联合放疗。患者显示出明显反应,无重大不良事件。

结论

本病例提示多西他赛、顺铂和5-氟尿嘧啶化疗联合放疗对前列腺鳞状细胞癌具有潜在疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/5585a834960f/IJU5-4-421-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/5494da08a152/IJU5-4-421-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/37d2e3247b14/IJU5-4-421-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/5585a834960f/IJU5-4-421-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/5494da08a152/IJU5-4-421-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/37d2e3247b14/IJU5-4-421-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e48/8560450/5585a834960f/IJU5-4-421-g002.jpg

相似文献

1
Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate.采用DCF化疗和放疗成功治疗原发性前列腺鳞状细胞癌。
IJU Case Rep. 2021 Aug 23;4(6):421-424. doi: 10.1002/iju5.12365. eCollection 2021 Nov.
2
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.多西他赛、顺铂和氟尿嘧啶化疗治疗转移性或不可切除的局部复发性肛门鳞状细胞癌(Epitopes-HPV02):一项多中心、单臂、Ⅱ期研究。
Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.
3
Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma.新型联合化疗与放疗治疗前列腺鳞状细胞癌
Int Cancer Conf J. 2016 Oct 11;6(1):25-28. doi: 10.1007/s13691-016-0266-6. eCollection 2017 Jan.
4
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.多西他赛、顺铂和5-氟尿嘧啶化疗对食管鳞状上皮细胞癌的疗效
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12485.
5
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.局部晚期头颈部鳞状细胞癌患者使用 FDG PET/CT 成像预测 DCF(多西紫杉醇、顺铂、5-氟尿嘧啶)诱导化疗后的生存情况。
Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1839-47. doi: 10.1007/s00259-012-2213-x. Epub 2012 Aug 16.
6
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.多西他赛对顺铂/5-氟尿嘧啶新辅助放化疗治疗食管鳞癌的附加作用。
Anticancer Res. 2022 Aug;42(8):3905-3911. doi: 10.21873/anticanres.15884.
7
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).多中心随机 II 期研究比较顺铂和氟尿嘧啶加多西他赛(DCF)与顺铂和氟尿嘧啶加阿霉素(ACF)作为可切除食管鳞癌(OGSG1003)术前化疗。
Ann Oncol. 2017 Jan 1;28(1):116-120. doi: 10.1093/annonc/mdw439.
8
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.多西他赛、顺铂和氟尿嘧啶新辅助放化疗(DCF-RT)治疗局部晚期食管鳞癌。
Cancer Chemother Pharmacol. 2019 Mar;83(3):581-587. doi: 10.1007/s00280-018-03764-4. Epub 2019 Jan 8.
9
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).多西他赛、顺铂和 5-氟尿嘧啶(DCF)化疗治疗转移性或不可切除的局部复发性肛门鳞状细胞癌:法国跨学科 GERCOR 和 FFCD 小组的 II 期研究(Epitopes-HPV02 研究)。
BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.
10
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.一项关于多西他赛、顺铂和氟尿嘧啶(DCF)诱导化疗后进行放化疗的前瞻性、多中心I/II期研究,该研究针对不可切除的局部晚期食管癌患者。
Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9. doi: 10.1007/s00280-016-3062-2. Epub 2016 May 18.

引用本文的文献

1
Locally Advanced Prostate Squamous Cell Carcinoma Diagnosed Using PET-CT and Treated With Robot-Assisted Radical Prostatectomy.使用PET-CT诊断并接受机器人辅助根治性前列腺切除术治疗的局部晚期前列腺鳞状细胞癌
IJU Case Rep. 2025 Aug 21;8(5):539-543. doi: 10.1002/iju5.70088. eCollection 2025 Sep.
2
Challenges in the diagnosis of primary squamous cell carcinoma of the prostate: a case report and literature review.前列腺原发性鳞状细胞癌诊断中的挑战:一例报告及文献综述
Front Surg. 2025 Jul 17;12:1532669. doi: 10.3389/fsurg.2025.1532669. eCollection 2025.
3
Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis.

本文引用的文献

1
Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma.新型联合化疗与放疗治疗前列腺鳞状细胞癌
Int Cancer Conf J. 2016 Oct 11;6(1):25-28. doi: 10.1007/s13691-016-0266-6. eCollection 2017 Jan.
2
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.顺铂和氟尿嘧啶单药或联合多西他赛诱导化疗治疗局部晚期头颈部鳞状细胞癌:TAX 324 随机 3 期试验的长期结果。
Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11.
3
前列腺混合性腺鳞状细胞癌,原发灶和肝转移灶均行配对测序。
Curr Oncol. 2024 Apr 24;31(5):2393-2399. doi: 10.3390/curroncol31050178.
4
Beyond the norm: exploring the uncommon squamous cell carcinoma of the prostate using a Saudi tumor registry.超越常规:利用沙特肿瘤登记处探索罕见的前列腺鳞状细胞癌
Ann Med Surg (Lond). 2023 Oct 2;85(12):5869-5873. doi: 10.1097/MS9.0000000000001220. eCollection 2023 Dec.
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.
前列腺鳞状细胞癌:联合化疗-放疗后的长期生存。
Radiat Oncol. 2007 Apr 3;2:15. doi: 10.1186/1748-717X-2-15.
4
Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature.前列腺鳞状细胞癌:2例报告并文献复习
J Urol. 1979 Jun;121(6):833-5. doi: 10.1016/s0022-5347(17)57013-5.